Carlos Barrios

发表

MIP-based optical sensing strategies: pros and cons

D. R. Walt, Victor Canalejas Tejero, M. C. Moreno Bondi, 2014 .

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Carlos Barrios, Toyoaki Hida, Keunchil Park, 2017, The Lancet.

Planning cancer control in Latin America and the Caribbean.

Richard Sullivan, Eduardo Cazap, Eduardo Rosenblatt, 2013, The Lancet. Oncology.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Lucio Crinò, Carlos Barrios, Johan Vansteenkiste, 2013, The Lancet. Oncology.